BiotechTube
ANYO Labs

ANYO Labs

Stockholm, Sweden· Est.
anyolabs.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4M

Overview

ANYO Labs is an early-stage, AI-driven drug discovery platform company based in Stockholm, Sweden. It has developed 'Anyo Technology,' a proprietary in silico screening platform that combines high-accuracy predictive models with unprecedented computational speed to generate, prioritize, and optimize novel drug candidates. The company is pre-revenue and focuses on partnering its platform to deliver preclinical candidates for challenging targets in record timelines. Its scientific foundation is strong, led by a pioneer in computational chemistry, Prof. Leif A. Eriksson.

DiagnosticsDigital Health

Technology Platform

Proprietary AI-driven in silico screening platform (Anyo Technology) combining generative AI for de novo molecule design, ultra-fast physics-based scoring, and predictive models for affinity, ADME, toxicity, and selectivity to accelerate hit-to-lead discovery.

Funding History

1
Total raised:$4M
Seed$4M

Opportunities

The unsustainable cost and failure rate of traditional drug discovery creates a massive market for AI-driven platforms that can improve R&D productivity.
ANYO's ultra-fast screening capability is particularly suited for exploring undrugged or challenging targets, a key unmet need.
Strategic partnerships with pharma and biotech firms offer a near-term path to validation and revenue.

Risk Factors

The platform's claims of speed and accuracy require extensive real-world validation against diverse biological targets.
The company operates in an intensely competitive AI drug discovery landscape against well-funded players.
As a pre-revenue startup, it faces significant funding and execution risk in translating its technology into commercially viable drug candidates.

Competitive Landscape

ANYO Labs competes in the crowded AI-driven drug discovery sector against public companies like Exscientia, Recursion, and Insilico Medicine, as well as numerous private startups and established computational chemistry software vendors. Its key claimed differentiators are the unprecedented speed of its proprietary scoring algorithm and its foundation in academic computational chemistry research from Swedish institutions.

More companies in AI / Machine Learning →More companies in Sweden →